UBS Upgrades Jazz Pharmaceuticals to Buy, Sets $307 Target
UBS has lifted Jazz Pharmaceuticals to Buy with a $307 price target, arguing that improving fundamentals and a stren...
Many budgets falter due to vague goals, rigidity, or inconsistent tracking. Here’s why Why Most Budgets Do Not Work and how to fix it.
27,770 articlesUBS has lifted Jazz Pharmaceuticals to Buy with a $307 price target, arguing that improving fundamentals and a stren...
Investors are shifting away from speculative hydrogen plays toward a blue-chip, high-yield industrial stock. Here’s w...
Dogecoin has fallen under the 10-cent threshold amid a broad risk-off in crypto markets. With no single catalyst, tra...
A little-known micro-cap trading under $30 is drawing renewed investor interest as quarterly results show improving p...
MARIS has launched a temporary fee waiver for new MLS subscribers, effective through late 2026, in a bid to simplify ...
Major U.S. banks are moving to launch a tokenized deposit network in 2027, aiming to bridge traditional payments with...
NVIDIA is expanding beyond GPUs into CPU territory, signaling a major strategic shift. This article explains what tha...
LG Electronics is moving to launch a blockchain-backed ad platform across its devices, aiming to create a shared ad-i...
XRP surged more than 13% in 24 hours, reclaiming the $1.28 level as sentiment improves and buyers return. On-chain da...
A fresh OpenAI policy hire has warned that government monopoly over frontier AI testing could slow innovation and rai...
A field-wide quantum ETF costs 0.40% and promises diversified exposure to IonQ and peers, challenging single-stock be...
Retirees with $1.3 million are recalibrating portfolios for steady income as markets swing. This piece highlights thr...